COVID-19 Blog
Microbix Collaborator Introduces New Lab Accreditation Program
Microbix Product Supporting Testing for Drug-Resistant Sexually-Transmitted Infection MISSISSAUGA, CANADA, April 25, 2024 – Microbix...
Microbix Corporate Presentation — April 2024
Microbix Biosystems Inc. - Our Company Today. Download The Presentation Here >>
Microbix Presenting at the 2024 Bloom Burton Conference
MISSISSAUGA, CANADA, April 11, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator,...
Episode 3: Diagnostics: Beyond the lab – Self-Collection with Copan Italia
Episode 6: Diagnostics Beyond the Lab: Bringing testing Closer to home
Microbix Announces Annual and Special Meeting Voting Results
MISSISSAUGA, April 1, 2024 - Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF) (“Microbix®” or the Company”), a life sciences innovator...
Microbix’s Clot-Buster Drug Project Advances
Sequel Pharma Executes Agreement with CDMO for Drug Substance Production MISSISSAUGA, CANADA, March 14, 2024 – Microbix Biosystems Inc....
Microbix Unveils Test Controls for Head and Neck Cancer
HPV-related Tissue-Sample Mimics for QC of histology and PCR analyses MISSISSAUGA, CANADA, March 11, 2024 – Microbix Biosystems Inc. (TSX:...
Microbix Enhances Quality Management System
ISO 13485:2016 Medical Devices Certification Attained TORONTO, December 24, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an...
Microbix Reports Record Results for Q1 Fiscal 2024
Record Revenues of $8.4 million and Record Net Income of $2.5 million MISSISSAUGA, CANADA, February 14, 2024 - Microbix Biosystems Inc....